GlassScriptPhysician profile
Michelle L Schaefer
NPI 1437507142
$1,287.27
in general payments reported to CMS, 2019-2025
20 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $118 · 2023: $541 · 2024: $387 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.83 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $287.16 | 2021-2023 | Xarelto |
| Janssen Biotech, INC. | $285.76 | 2022-2024 | Imbruvica, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $162.67 | 2023-2025 | Calquence |
| Merck Sharp & Dohme LLC | $101.77 | 2023-2024 | Keytruda |
| Incyte Corporation | $78.26 | 2023 | Monjuvi |
| Celgene Corporation | $50.96 | 2024 | Reblozyl |
| Genentech USA, INC. | $41.49 | 2023-2024 | Phesgo |
| Menarini Silicon Biosystems, INC. | $35.65 | 2023-2024 | Cellsearch |
| Abbvie INC. | $33.06 | 2025 | |
| Seagen INC. | $32.00 | 2023 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $25.12 | 2024 | Alunbrig |
| Syndax Pharmaceuticals, INC. | $21.60 | 2025 | Revuforj |
| Grifols USA, LLC | $21.29 | 2024 | Gamunex-C |
| Pfizer INC. | $18.93 | 2024 | |
| Tersera Therapeutics LLC | $16.97 | 2025 | Zoladex |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.03 | 2023 | Zejula, Jemperli |
| Stemline Therapeutics INC. | $15.19 | 2023 | Orserdu |
| Kyowa Kirin, INC. | $15.01 | 2024 | Poteligeo |
| Genzyme Corporation | $14.53 | 2025 | |
| Pharmacosmos Therapeutics INC. | $13.82 | 2024 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.